AIS
GTBP icon

AM Investment Strategies’s GT Biopharma GTBP Stock Holding History

AM Investment Strategies’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Hold
15,000
– – ﹤0.01% 114
2026
Q1 		$6K Hold
15,000
– – ﹤0.01% 111
2025
Q4 		$12K Buy
+15,000
New +$10.7K ﹤0.01% 116

Other funds holding GTBP

EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
KP
Kitching Partners Conshohocken, Pennsylvania $116M AUM 16.12% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return
SWP
Sagespring Wealth Partners Franklin, Tennessee $6.51B AUM 23.96% 1-Year Est. Return
TWP
Tempus Wealth Planning Irvine, California $511M AUM 28.39% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.9B AUM 36.41% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return

AM Investment Strategies's GTBP Position: Q2 2026 in Review

AM Investment Strategies held its GT Biopharma (GTBP) position steady in Q2 2026 at 15,000 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #114.

AM Investment Strategies first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $12K in Q4 2025. 19 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • AM Investment Strategies held 15,000 shares of GT Biopharma worth $7K as of Q2 2026.
  • AM Investment Strategies left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of AM Investment Strategies's portfolio in Q2 2026, its #114 holding.
  • AM Investment Strategies first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • AM Investment Strategies's GT Biopharma position peaked at $12K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on AM Investment Strategies's 13F filing for Q2 2026, filed 16 Jul 2026.